In Brief
The contribution of the glioblastoma cell of origin for disease progression and treatment response remains unclear. Jiang et al. find that the originating cell type affects mouse glioblastoma tumorigenicity and drug sensitivity and validate this using transcriptome and functional analyses on a large panel of human glioblastoma cell lines.
SUMMARY
The identity of the glioblastoma (GBM) cell of origin and its contributions to disease progression and treatment response remain largely unknown. We have analyzed how the phenotypic state of the initially transformed cell affects mouse GBM development and essential GBM cell (GC) properties. We find that GBM induced in neural stem-cell-like glial fibrillary acidic protein (GFAP)-expressing cells in the subventricular zone of adult mice shows accelerated tumor development and produces more malignant GCs (mGC1 GFAP ) that are less resistant to cancer drugs, compared with those originating from more differentiated nestin-(mGC2 NES ) or 2, 0 3 0 -cyclic nucleotide 3 0 -phosphodiesterase (mGC3 CNP )-expressing cells. Transcriptome analysis of mouse GCs identified a 196 mouse cell origin (MCO) gene signature that was used to partition 61 patient-derived GC lines. Human GC lines that clustered with the mGC1 GFAP cells were also significantly more self-renewing, tumorigenic, and sensitive to cancer drugs compared with those that clustered with mouse GCs of more differentiated origin.
INTRODUCTION
Glioblastoma (GBM) is the most frequent and aggressive primary malignant brain tumor (Ostrom et al., 2015) . It is highly treatment resistant, has very poor prognosis, and is essentially uniformly lethal (Ostrom et al., 2015) . A great challenge for therapy development is the large degree of GBM heterogeneity, both within and between tumors. An extensive body of work has shown that the GBM intertumor heterogeneity to a large extent is caused, to a large extent, by the genetic and epigenetic alterations that are found in these tumors (Brennan et al., 2013; TCGA, 2008; Verhaak et al., 2010) . Despite the high diversity, adult GBMs can be divided into four to five molecular subtypes based on gene expression profiling (Brennan et al., 2013; Verhaak et al., 2010) . These subtypes help delineate the major molecular pathways of GBM biology but are, as yet, of little relevance for treatment or prognosis. Studies of intratumor heterogeneity have shown that different molecular subtypes are present in different parts of the same tumor (Sottoriva et al., 2013) or even in individual cells within a single tumor (Patel et al., 2014) . Another cause of GBM heterogeneity is the presence of GBM stem cells (GSCs) (Singh et al., 2004) . GSCs are a subset of glioma cells that have the capacity to regenerate orthotopic glioma in immune-deficient mice showing the same characteristics as the primary tumor (Vescovi et al., 2006) . They have been shown to escape irradiation (Bao et al., 2006) and chemotherapy (Bleau et al., 2009) , and are believed to give rise to tumor recurrence (Chen et al., 2012) . GSCs, which are most effectively maintained in culture using NSC (neural stem cell) medium (Lee et al., 2006) , also share other features with NSCs (Vescovi et al., 2006) such as expression of various NSC markers, which have been used to prospectively sort GSCs from the tumor bulk (Singh et al., 2004) . However, to date, no universal GSC marker has been identified, which further underlines the large heterogeneity of GBM.
The cell of origin for GBM has not been formally proven but is proposed to be an NSC, glial precursor cell (GPC), or more differentiated glial cell type. This generally accepted view is based on numerous observations such as: (1) the morphology and CNS marker expression in GBM tissues and cells are similar to that of normal neural and glial cell types (Louis et al., 2007) ; (2) the relationship between the transcriptomes of different GBM subtypes and those of various normal glial cell types (Verhaak et al., 2010); and (3) Llaguno et al., 2015; Friedmann-Morvinski et al., 2012; , and oligodendrocyte precursor cells (OPCs) (Lindberg et al., 2009; Liu et al., 2011; Persson et al., 2010) have the capacity to develop glioma. In addition, the fact that isocitrate dehydrogenase (IDH)-mutated GBMs are molecularly, biologically, and clinically very different from IDH wild-type tumors (Ceccarelli et al., 2016) and the recent finding proposing that the cell of origin may determine the molecular subtype (Alcantara Llaguno et al., 2015) , further support that GBM could stem from several cell types and suggest that the originating cell could have important implications for GBM biology and heterogeneity (Alcantara Llaguno et al., 2015; Sutherland and Visvader, 2015) . We have also recently shown that the cell of origin affects the tumor phenotype in mouse models of pediatric supratentorial high-grade glioma (Sreedharan et al., 2016) . Together, this argues for the importance of a deeper knowledge about the nature and consequences of the cell of origin in GBM.
By using a cross-species strategy, we addressed the question of how different glial cell types contribute to the heterogeneity of GBM cell (GC) phenotypes. We have performed in-depth analyses of the consequences of different cells of origin for mouse GBM development and GC properties. Through differential gene expression analyses of mouse GCs, we identified a gene signature that was used to stratify human GCs into subgroups that displayed similar phenotypic properties as their mouse counterparts.
RESULTS

GBM Development in Adult Mice Is Accelerated When Induced in More Immature Glial Cells
We used the replication-competent leukosis virus splice acceptor (RCAS)/tv-a mouse glioma model, where transgenic expression of the avian tv-a receptor renders cells susceptible to RCAS viral vectors. Three different tv-a transgenic mouse strains were used in which expression of tv-a is under the control of the glial fibrillary acidic protein (GFAP) promoter in the G/tv-a line , the nestin (NES) promoter in the N/tv-a line , or the 2 0 ,3 0 -cyclic nucleotide 3 0 -phosphodiesterase (CNP) promoter in the C/tv-a line (Lindberg et al., 2009) , directing RCAS infection to GFAP-, NES-, or CNP-expressing cells, respectively. All mice were in a homozygous p19
Arf -deficient (Arf À/À ) background. To obtain a localized RCAS infection, chicken fibroblast cell line (DF-1) chicken fibroblasts producing RCAS virus were transplanted through intracerebral stereotactic injections to adult mice. RCAS is replication incompetent in mammalian cells (Federspiel et al., 1994) , and infection of target cells will occur during a few days after injection.
First, we characterized the mouse CNS cells infected by RCAS in the different mouse strains. To target NSCs (Doetsch et al., 1999) and OPCs (Komitova et al., 2009) , DF-1 cells producing RCAS-eGFP were injected in the subventricular zone (SVZ) of adult G/tv-a;Arf À/À (G/tv-a_SVZ) and C/tv-a;Arf À/À mice (C/tv-a_SVZ), respectively. To target other types of glial cells, RCAS-eGFP was also injected in the retrosplenial cortex (CTX) of adult N/tv-a;Arf À/À mice (N/tv-a_CTX), a location at a distance from and superior-anterior to the SVZ. The brains were analyzed 1 week post-infection by immunostainings for GFP and various neural and glial markers (Figures 1A, 1C, 1E, 1G, and 1I) . Infected mouse cells could easily be distinguished from the residual, small, round, and intensely GFP-positive injected DF-1 cells by their larger, more heterogenous morphology with ample extensions, further supported by double-immunofluorescence stainings for chicken vimentin (c-vim, specific to DF-1 cells) and GFP ( Figure S1A ). The results from the double immunostainings for neural and glial markers and GFP were quantified by relating the number of double-positive cells to the number of GFP singlepositive cells with neural or glial morphology ( Figures 1B, 1D , 1F, 1H, and 1J). In G/tv-a_SVZ and N/tv-a_CTX brains, but not in C/tv-a_SVZ brains, we detected double-positive cells for both GFP and GFAP, and GFP and NES ( Figures 1A-1D ). This was expected because it is well established that GFAP and NES have an overlapping expression in adult NSCs and GPCs (Doetsch et al., 1999) . Expression of the late OPC marker CNP was specific for the C/tv-a_SVZ brains (Figures 1E and 1F) , whereas the more immature GPC marker OLIG2 (Zhou et al., 2001 ) was co-detected with GFP in N/tv-a_CTX and C/tv-a_SVZ brains ( Figure 1G ), but only rarely in G/tv-a_SVZ brains ( Figure 1H ). SRY-box2 (SOX2), a marker for neural stem and progenitor cells (Graham et al., 2003) could be found in all three mouse lines ( Figure 1I ). However, the number of GFP and SOX2 double-positive cells was significantly higher in G/tv-a_SVZ compared with N/tv-a_CTX or C/tv-a_SVZ brains ( Figure 1J ). Additionally, we stained for NG2, CD15, and TUJ1, but could not detect any GFP-positive cells expressing these markers ( Figures S1B-S1D (Figure 2A ). PDGFB has a retention motif at the C-terminal domain that causes binding of secreted platelet-derived growth factor B homodimers (PDGF-BB) to the outer cell membrane of producing cells (LaRochelle et al., 1991) ; thus, tumors will be induced by autocrine PDGF-BB stimulation of RCASinfected cells. Injected mice developed brain tumors with significantly different survival, with G/tv-a_SVZ mice showing the shortest latency ( Figure 2B ). To analyze whether the different microenvironments in CTX and SVZ locations would affect tumor development, we also injected RCAS-PDGFB in the SVZ of N/tv-a;Arf À/À mice and found no difference in survival ( Figure S2 ). Tumors induced in G/tv-a_SVZ and N/tv-a_CTX mice tended to be more malignant (although not significant) than those developing in C/tv-a_SVZ mice ( Figure 2C ). This study is focused on GBM (grade IV glioma) ( Figure 2D ) and when analyzing grade IV tumors only, the significant difference in survival remained ( Figure 2E ). GBMs of different origin were histologically inseparable ( Figure 2D ), and from many of them GC cultures were established in serum-free defined NSC medium, but without addition of epidermal growth factor (EGF) and fibroblast growth factor 2 (FGF2) (Jiang et al., 2011) . The GC cultures from G/tv-a_ SVZ, N/tv-a_CTX, and C/tv-a_SVZ were named mGC1 GFAP , mGC2 NES , and mGC3 CNP , respectively, to indicate the different GBM origins (Figure 2A ). At least three cultures from independent tumors in each group (mGC1 GFAP , mGC2 NES , and mGC3 CNP ) were established and used in the subsequent analyses. All cultures displayed tumor-initiating capacity following intracranial injection of 1 3 10 4 cells to syngeneic newborn mice ( Figure 2F ). In accordance with the survival of In each group, three independently established GC cultures were analyzed. n, total number of mice injected in each group. Log rank test was performed to compare the mouse survival, and statistical significance is indicated as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. See also Figure S2 .
the primary RCAS-induced GBMs (Figure 2E) , mGC1 GFAP cells generated secondary tumors at a significantly faster rate than mGC2 NES and mGC3 CNP cells ( Figure 2F ). This argued that the accelerated primary tumor development in G/tv-a_SVZ mice compared with N/tva_CTX and C/tv-a_SVZ mice ( Figure 2A ) was likely due to inherent properties of mGC1 GFAP cells, making them more malignant and not the result of, e.g., a higher number of RCAS-infected cells in the G/tv-a;Arf À/À mice. It also suggested that important intrinsic tumor cell properties could be maintained in stem cell culture.
The Cell of Origin for GBM Affects Self-Renewal, Proliferation, and Differentiation of GCs To analyze the cause for the varying tumorigenic capacities of mouse GCs of different origin, we assessed the sphere-forming ability and proliferation rate of primary GC cultures at clonal density (1,000 cells/mL). Freshly explanted mGC1 GFAP cells showed a significantly higher primary sphere-forming ability ( Figure 3A ) and generated larger spheres ( Figures 3B and 3C ) than mGC2 NES and mGC3 CNP cells. This difference was even more pronounced when analyzing secondary sphere-forming ability ( Figure 3D ), and only mGC1 GFAP cells could be extensively passaged as spheres (data not shown). Thus, all subsequent experiments had to be performed on adherently cultured cells. We All experiments were performed at least three times except for the differentiation analysis that was repeated twice. Values represent the mean ± SEM. The unpaired t test was performed, and statistical significance is indicated as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. n, number of independently established cell cultures that were examined. See also Figures S3-S5.
found that also in adherent cultures, the difference in sphereforming ability remained between the groups. Results from limiting dilution assays showed that mGC1 GFAP cells had a significantly higher self-renewal capacity than mGC2 NES and mGC3 CNP cells ( Figure 3E ). A proliferation assay sustained the notion that mGC1 GFAP cells had a higher proliferation rate than the mGC2 NES and mGC3 CNP cells ( Figure 3F) . The difference in self-renewal indicated that the mGC1 GFAP cells would be more stem-like. Therefore, we analyzed the protein expression of the NSC markers NES, SOX2, BMI1, and MSI1, and found that all mGC cultures, regardless of origin, had an equally high expression in essentially all cells of these markers (Figures S3A-S3D ). Furthermore, there was no differences in primary and secondary sphere-forming ability or the size of the spheres in NSC cultures established from the SVZ of N/tv-a;Arf
, and C/tv-a;Arf À/À mice ( Figures   S4A-S4D) , excluding that the different genetic backgrounds of the mouse strains had produced the phenotypes observed in the mGC cultures. The ability of aberrant differentiation when cultured in fetal bovine serum (FBS) is a key characteristic of GSCs. Consistent with previous findings (Jiang et al., 2011) , we found that all of our mGC cultures displayed dramatic changes in morphology and expression of glial and neuronal markers such as GFAP, TUJ1, CNP, SOX2, and NES when cultured in 5% FBS (Figure S5 ). Interestingly, a 16 hr pulse of bromodeoxyuridine (BrdU) showed that, although proliferation was almost completely suppressed in the serum-cultured mGC2 NES and mGC3 CNP cells, mGC1 GFAP cells maintained a considerable proliferation activity ( Figures 3G and 3I) . Thus, GCs of a less differentiated origin were remarkably more resistant to proliferative arrest in response to serum-induced differentiation.
Taken together, our in vitro cell analyses showed that a GBM originating from an immature NSC-like cell had a higher frequency of GSCs in their tumors, and cultured cells from these tumors displayed increased self-renewal and proliferative capacities compared with those of a more differentiated, glial precursor cell origin.
Transcriptome Analysis Identifies a 196 Mouse Cell
Origin Gene Signature Collectively, our data suggested that the cell of origin could determine important GBM cell properties. To uncover the molecular events underlying the different phenotypes, we performed transcriptome analyses on three independent GC cultures of each cell of origin group (mGC1 GFAP , mGC2 NES , and mGC3 CNP ) and three NSC cultures (mNSC G/tv-a , mNSC N/tv-a , and mNSC C/tv-a ), one from each of the three mouse lines. Principal component analysis (PCA) performed on the global gene expression profiles showed a clear separation between the mGC groups of different origin (mGC1 GFAP , mGC2 NES , and mGC3 CNP ), as well as a separation between all mGCs and the mNSC group of cells, collectively called mNSC4 ( Figure 4A ). A list of 196 genes that were differentially expressed among the mGC1 GFAP , mGC2 NES , and mGC3 CNP groups was identified and referred to as the 196 mouse cell origin (MCO) gene signature (Table S1 ). A heatmap of Z scores for the 196 MCO signature genes across the 12 mouse samples showed different patterns of gene expression between the different mGC and mNSC groups ( Figure 4B) .
The 196 MCO genes were distributed throughout the mouse genome with the largest numbers on chromosomes 7 and 10 (14 each). To identify candidate markers that could best differentiate between mGC groups, we sorted the log2 fold-change (logFC) values of the 196 MCO genes and selected the top 25% and bottom 25% genes in each mGC group, resulting in a list of 98 genes (top-98). A Venn diagram shows the overlap of the top-98 genes, where 48 genes were over-or under-expressed in only one mGC group ( Figure S6A ). Functional annotation of the top-98 genes from each mGC group (Table S2) by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway using DAVID (Huang da et al., 2009 ) detected a number of enriched GO terms associated with signaling, morphogenesis, and differentiation, and KEGG pathways such as hedgehog signaling and pathways in cancer (e.g., DCC, GLI3, and GPC3 are putative markers of the mGC1 GFAP cluster). Moreover, over-representation analysis of the entire MCO gene list using the ConsensusPathDB (Kamburov et al., 2013 ) and the Reactome pathway-based sets produced nine enriched pathways ( Figure S6B ) including several signaling pathways. Functional annotation with Disease Ontologies using FunDO (Du et al., 2009) (Figure S6C) showed that several MCO genes were associated with terms such as ''brain tumor,'' ''breast cancer,'' and ''cancer.'' In all, these analyses supported that mouse GBMs of different origins are transcriptionally distinct and suggested that the 196 MCO gene signature could represent a basis for stratifying other GBM cases.
Molecular Subtype Prediction Reveals a Relation of Mouse GCs to Human GBM Subtypes That Is Dictated by the Cell of Origin
To investigate the relationship of our mouse GBM models to The Cancer Genome Atlas (TCGA) GBM subtypes, we compared the expression profiles of the human genes used for molecular subtype classification (Verhaak et al., 2010) in mRNA data from 515 human TCGA GBM samples (of which the vast majority had wild-type IDH1/IDH2; see Supplemental Experimental Procedures) and our 9 mGC samples (3 mGC1 GFAP , 3 mGC2 NES , and 3 mGC3 CNP ) and 3 mNSC samples (mNSC G/tv-a , mNSC N/tv-a , and mNSC C/tv-a ) ( Figure 4C ). An isomap analysis (Tenenbaum et al., 2000) (a dimensionality reduction method well suited to visualize similarities and differences between groups of cancer samples; Nilsson et al., 2004) demonstrated that while the mGC1 GFAP and mGC3 CNP groups clustered together with proneural GBM samples, the mGC2 NES group was closer to mesenchymal GBMs. The mNSC cultures clustered close to the classical GBMs that have a higher frequency of epidermal growth factor receptor (EGFR) alterations compared with the other subtypes Verhaak et al., 2010) . This seemed reasonable given that these immortal (because of Arf loss) NSCs, unlike the mGCs, were dependent on EGF and had to be cultured in regular NSC medium with EGF and FGF2. The cross-species analysis showed that our mouse models could capture a considerable part of the complexity of human GBM and suggested that the cell of origin has a direct influence on the subtype of the tumor, in line with a recent The analysis is based on the Z scores of mRNA expression for 728 TCGA subtype classifier genes that were represented on the Affymetrix mouse array. For each mGC group, three independent cultures were included in the analysis. The differential gene expression analysis was performed using the three mNSC cultures (mNSC G/tv-a , mNSC N/tv-a , mNSC C/tv-a , i.e., one from each of the G/tv-a;Arf
, and C/tv-a;Arf À/À mouse lines) as reference. See also Figure S6 and Table S1 . (Xie et al., 2015) (Table S3 ). Thirty MCO genes had to be excluded because they were not represented on the microarray used for human cell line transcriptome profiling.
The expression values of the remaining 166 MCO genes were extracted from the transcriptome data and converted into Z scores within each dataset, across the 61 human glioblastoma cell culture (hGC) lines and across the 12 mouse samples (3 mGC1 GFAP , 3 mGC2 NES , 3 mGC3 CNP , and 3 mNSC) respectively, and combined ( Figure 5A ). The resulting matrix was subjected to consensus clustering (Monti et al., 2003) with an optimal k = 4 ( Figure 5B ). The resulting four clusters were called cluster 1 GFAP , cluster 2 NES/CNP , cluster 3, and cluster 4 ( Figure 5C ). Clusters 1-3 contained hGCs of different TCGA subtypes ( Figure 5D ), and cluster 4 consisted of mNSC cells only. Cluster 1 GFAP was the largest (n = 27), followed by cluster 2 NES/CNP (n = 18) and cluster 3 (n = 15). The MCO clusters showed a clear separation also in an isomap analysis using the same combined matrix of Z scores for the 166 MCO genes ( Figure 5E ), providing further support for the grouping.
Human GC Lines of Cluster 1 GFAP Have Higher Self-Renewal and Are More Malignant Than Those of Cluster 2 NES/CNP We reasoned that the molecular differences between hGC lines of cluster 1 GFAP and cluster 2 NES/CNP would also be reflected in their phenotypes. At least six hGC lines from each cluster were analyzed, and we aimed to cover the proportion of TCGA subtypes present in each cluster. Immune-deficient mice were injected intracerebrally with either hGC1 or hGC2 lines, and approximately one litter of mice was injected with each cell line ( Figure S7 ). Analysis of survival comparing mice injected with hGC1 or hGC2 lines showed that cell lines of the hGC1 group produced a significantly shorter survival ( Figure 6A ), which is in line with comparing the mGC1 GFAP cells with the mGC2 NES or mGC3 CNP cells ( Figure 2F ). Furthermore, we could also show that the hGC1 lines contained a significantly higher frequency of self-renewing cells than the hGC2 lines by limiting both dilution assay ( Figure 6B ) and primary ( Figure 6C ) and secondary sphere-forming assays ( Figure 6D ), also mimicking the corresponding mouse data ( Figures 3E, 3A , and 3D, respectively). However, unlike the mGC cells (Figure 3F) , human GC lines of the hGC1 group did not show a proliferation advantage over those in the hGC2 group (Figure 6E) . The fact that hGC1 lines had higher self-renewal and were more malignant than hGC2 lines prompted us to analyze the survival of all patients from which the hGC1 and hGC2 cell lines were derived. This showed, somewhat surprisingly, that the more malignant phenotype of the cell lines in the hGC1 group were not reflected in different (shorter) survival of hGC1 patients ( Figure 6F ).
Human GC Lines of Cluster 2 NES/CNP Display a Higher General Resistance to Drugs Compared with Those of Cluster 1 GFAP
The absence of survival advantage for hGC2 patients despite their less malignant GCs proposed that there could be a difference in treatment response between patients in the hGC1 and hGC2 groups. To test the general drug resistance of mouse and human GCs of different origin, we used a panel of 26 compounds chosen to target a broad range of mechanisms relevant to cancer cells (Tables S4-S6) . We tested three cell cultures each from the mGC1 GFAP , mGC2 NES , and mGC3 CNP groups comparing the response of mGC1 GFAP with the combined response of mGC2 NES +mGC3 CNP cells (Table S4) , and seven hGC1 lines that were compared with six hGC2 lines (Tables S5  and S6 ). From the dose-response curves for each cell line, the area under the curve (AUC) was calculated. AUC measures both potency and efficacy of a drug, and is often used to compare the effect across multiple cell lines (Fallahi-Sichani et al., 2013) . AUC values for each drug were compared using a two-sample unpaired Student's t test and a significance level of 0.05 ( Figures 7A and 7B ). For mGCs, 13 out of 26 drugs showed a significant difference in drug response comparing mGC1 GFAP with the combined result of mGC2 NES and mGC3 CNP cells ( Figure 7A ). For human GCs, there was a significant difference in drug response between the hGC1 and hGC2 groups for melflufen, temozolomide, 6-thioguanine, and b-AP15 (Figure 7B) . In all these cases, the mGC1 GFAP /hGC1 cells were more sensitive than the mGC2 NES +mGC3 CNP /hGC2 cells. To investigate the general trend in drug response, we plotted, for each drug, the median AUC values for mGC1 GFAP or hGC1 cells (x axis) versus the median AUC values for mGC2 NES +mGC3 CNP or hGC2 cells (y axis) ( Figures 7C and 7D ). The Spearman's rank correlation coefficient rho was equal to 0.91 (p = 9.5 3 10
À11
) for mGCs and 0.81 (p = 6.6 3 10 À7 ) for hGCs, and the fitted linear regression line had a slope of 0.74 for mGCs and 0.65 for hGCs, which indicated (slope value < 1) that the mGC1 GFAP and hGC1 cells were generally more sensitive to the compounds tested than mGC2 NES +mGC3 CNP and hGC2 cells, respectively. Tables S1 and S3. Taken together, our results show that the originating cell type may contribute to the general drug response phenotype of GCs, where cells originating from immature glial cells tend to be more sensitive to drugs than those originating from more differentiated cell types.
DISCUSSION
We have assessed how three different cells of origin targeted by the same oncogenic alterations contribute to GBM development and the phenotypic properties of GBM cells. The cell of origin in this study was defined as the cell that receives the initial oncogenic mutation (the RCAS-infected cell). Our data demonstrate a functional relationship between the cell of origin for mouse GBM and the phenotype of GBM cells that could be molecularly captured in the 196 MCO gene signature. By cross-species analysis, we used the 196 MCO signature to separate patient-derived GBM cells into functionally distinct groups. Our findings may provide the basis for an improved patient stratification and for identifying new targets for therapy. Relating the mouse GBM models used to the TCGA subtypes showed that mGC1 GFAP and mGC3 CNP cultures clustered with the proneural subtype, in line with previous data (Ozawa et al., 2014) . Curiously, we found that the mGC2 NES cultures were grouped with the mesenchymal subtype. Mesenchymal GBMs have been shown to be molecularly related to cultured astroglial cells (Verhaak et al., 2010) , which are suggested to represent astrocyte precursor cells (Cahoy et al., 2008) . This fits well with the origin of the mGC2 NES cells being glial precursor cell-like toward the astrocyte lineage. The fact that we could model different GBM subtypes by initiating the tumor in different cell types suggests that the combination of cell of origin and oncogenic mutations are key factors in defining tumor phenotypes, in line with previous studies (Alcantara Llaguno et al., 2015; Ghazi et al., 2012; Wang et al., 2013) . This also clearly demonstrated, as we had expected, that the three mouse models used could not cover the full spectrum of human GBM diversity. In that sense, our study should be viewed as a proof of concept, and further GBM modeling using different mutations will be needed in order to generate a comprehensive stratification based on the cell of origin.
Self-renewal and tumorigenicity are required characteristics of GSCs (Singh et al., 2004; Vescovi et al., 2006) , and our results showed that these properties were strongly associated with the differentiation stage of the cell of origin. An immature, NSC-like origin generated primary GBMs faster, and the resulting mouse GCs had higher self-renewal abilities and accelerated tumor-initiating properties than those of glial precursor cell origin. Interestingly, GCs of all origins displayed uniform and (D) Secondary sphere-forming ability after plating 5 3 10 2 dissociated cells from the primary spheres of hGC1 (n = 7) and hGC2 (n = 6) lines.
(E) Proliferation analysis measuring the total number of cells after 7 days of adherent culture of hGC1 (n = 9) and hGC2 (n = 6) cell lines. Student's t test, p = 0.8296. (F) Kaplan-Meier graph showing glioma-free survival of patients from which the hGC1 and hGC2 lines were derived. n, total number of patients in each group. Log rank test, p = 0.6745. Three patients in the hGC1 group were still alive at the breakpoint for patient data extraction. All experiments were repeated twice; values represent the mean ± SEM. The unpaired t test was performed, and statistical significance is indicated as follows: *p < 0.05; **p < 0.001. See also Figure S7 and Table S3 . All experiments were performed twice using duplicate samples. The compounds were applied for 24 hr, and cell survival was measured by FMCA after 72 hr. One putative cause of the inability of the MCO stratification to predict patient survival between cluster 1 GFAP /hGC1 cells and cluster 2 NES/CNP /hGC2 cells, in spite of the hGC1 cells being significantly more malignant in experimental analyses, was the difference in drug sensitivity. The dose-response analysis of 13 hGC lines to 26 compounds, most being in clinical use or in clinical trials for treating cancer, clearly showed that the hGC1 lines had a higher general sensitivity to drugs than the hGC2 lines. Furthermore, hGC1 cell lines were significantly more sensitive than hGC2 lines to temozolomide, which indicates that hGC1 patients could have responded better to therapy than hGC2 patients, providing an explanation to the lack of survival difference between the MCO groups. This suggests that understanding the mechanisms regulating the interplay between stemness and drug sensitivity could be important for developing more effective drugs against subgroups of GBM. Further exploration of the MCO gene signature has the potential to uncover genes and pathways that could be of value as functional and/or predictive biomarkers in GBM.
The highly inter-and intratumoral heterogeneous nature of this disease has posed a great challenge to the development of more efficient and specific therapies. Our results suggest that if the functional consequences of the originating cell type can be deciphered, it could add to the understanding of the mechanisms behind intertumoral heterogeneity and contribute to future evolution of targeted therapies for stratified groups of GBM patients.
EXPERIMENTAL PROCEDURES
For detailed descriptions, see Supplemental Experimental Procedures.
Infection of tv-a Transgenic Mice
Animal experiments were performed in accordance with the rules and regulations of Uppsala University and were approved by the local animal ethics committee. Six-to eight-week-old N/tv-a;Arf À/À (Uhrbom et al., 2005) , G/tv-a; Arf À/À (Uhrbom et al., 2005) , and C/tv-a;Arf À/À (Lindberg et al., 2014) mice were used. RCAS-producing DF-1 cells (RCAS-eGFP or RCAS-PDGFB-HA, gifts from Eric Holland) were transplanted by stereotaxic injections of 10 5 cells in 2 mL PBS. In G/tv-a;Arf À/À and C/tv-a;Arf À/À mice, the coordinates were:
0.5 mm anterior of bregma, 1.1 mm lateral, and 2.5 mm ventral ( = SVZ). In N/tv-a;Arf À/À mice, the coordinates were: 3 mm posterior of bregma, 0.5 mm lateral, and 1 mm ventral ( = CTX). Mice injected with RCAS-eGFP were killed 1 week after injection, and mice injected with RCAS-PDGFB-HA were monitored every second day and killed upon symptoms of illness.
Mouse GBM Cell and NSC Cultures
Tumor and control cells were explanted and cultured from mouse primary tumor tissues or the SVZ of uninjected mice as described previously (Jiang et al., 2011) . Tumor cells were cultured without adding exogenous EGF and FGF2, whereas non-tumor cells were cultured with addition of EGF and FGF2.
Human GBM Cell Cultures All handling of human tissues and data were in accordance with the protocol approved by the Uppsala ethical review board (2007/353) . Samples from patients diagnosed with primary GBM were anonymized, coded, explanted, and cultured in serum-free defined NSC medium as previously described (Xie et al., 2015) . All experiments were performed on cells at passages 8-15.
Intracranial GBM Cell Transplantation
Intracranial cell transplantations of mouse or human GBM cell cultures were performed in neonatal syngeneic (for mGCs) or non-obese diabetic-severe combined immunodeficiency (NOD-SCID) (for hGCs) mice as previously described (Jiang et al., 2011) .
Sphere-Forming, Proliferation, and Differentiation Analyses Single-cell suspensions from primary mouse GBMs or human GC lines were seeded at 1,000 cells/well or 500 cells/well, respectively, in 24-well plates. For mGCs, the number and size of spheres were determined on day 7, after which they were dissociated and seeded for secondary sphere-forming assay. For hGCs, the number of spheres was determined on day 14, after which secondary sphere-forming analysis was performed. For proliferation analysis, 10 5 mGCs or hGCs were seeded in six-well plates and the total cell number was determined on day 7. For differentiation analysis, mGCs were seeded onto extracellular matrix (ECM)-coated glass coverslips and cultured in NSC medium with or without 5% fetal bovine serum for 7 days. BrdU was added 16 hr before fixation. All experiments on mGCs were performed in at least duplicates on at least three cell cultures from independent tumors in each group (mGC GFAP , mGC NES , and mGC CNP ) and were repeated at least twice. All experiments on hGCs were performed in at least duplicates and repeated twice.
Microarray Analyses
Total mRNA was extracted using the QIAGEN RNeasy kit (QIAGEN) from 9 mouse GC cultures, 3 mouse NSC cultures, and 61 human GBM cell lines. The RNA was labeled and hybridized on Affymetrix Mouse Gene ST 1.0 arrays (mouse samples) or Affymetrix Human Transcriptome 2.0 arrays (human samples) at the SciLifeLab Array and Analysis Facility. The raw data were normalized using the Affymetrix Expression Console software (http://www.affymetrix. com/estore) using the robust multi-array average method (Li and Wong, 2001 ). All subsequent data processing and analyses were carried out in R using packages available from the Bioconductor project (https://www.bioconductor.org) and MATLAB (version R2014b; The MathWorks).
Identification of the 196 MCO Gene Signature
To identify the genes that distinguish among the mGC1 GFAP , mGC2 NES , and mGC3 CNP cells, while excluding the influence of the genetic background, we performed a differential gene expression analysis using the R limma package (Wettenhall and Smyth, 2004) between the samples in each group and the mNSC samples used as reference. We selected the genes that showed, in any of the three comparisons, a log2 fold-change (logFC) greater than 1 or smaller than À1 (at an adjusted p < 0.01 corresponding to a false discovery rate [FDR] of 1%). For each of these genes we computed the difference in logFC values between pairs of groups (mGC1 GFAP versus mGC2 NES , mGC2NES versus mGC3 CNP , and mGC1 GFAP versus mGC3 CNP ) and selected those for which the difference was at least greater or smaller than one unit. We (C and D) The median AUC values were plotted for (C) mGC1 GFAP (on the x axis) against mGC2 NES +mGC3 CNP (on the y axis) for each of the 26 drugs, and for (D) hGC1 (x axis) against hGC2 (y axis). This highlights the general trend showing that most drugs produce a lower median AUC value (higher drug sensitivity) in mGC1 GFAP /hGC1 cells. A diagonal line (corresponding to a hypothetical case of equal median values between groups) is plotted in red, and the linear regression line fitted to all the median pairs is plotted in blue.
See also Tables S3-S6. further filtered this list to eliminate non-coding sequences and genes with an SD greater than 1.5 among the Z scores of the replicates within a group.
Drug Response Analysis
We used a panel of 26 selected anti-cancer agents and experimental compounds (Tables S4-S6 ). The experiment was done in duplicates and repeated twice for all GBM cell lines. Cell survival was measured using the non-clonogenic fluorometric microculture cytotoxicity assay (FMCA).
Statistical Analyses
Statistical analysis were performed using GraphPad Prism (GraphPad Software) and R (for the Kruskal-Wallis test, Shapiro-Wilk test, Spearman's rank correlation, and linear modeling). Figures containing data from multiple experiments are presented as mean ± SD, and the statistical significance of differences between group means was determined with the two-tailed unpaired Student's t test. For the drug analysis, Student's t test was used for 20 drugs that fulfilled the normality assumption and the non-parametric Kruskal-Wallis for the other 6. The survival curves of mice and patients were analyzed by log rank test. The following p values indicate statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
ACCESSION NUMBERS
The accession number for the gene expression profile data generated by microarray analysis reported in this paper is NCBI GEO: GSE91393. 
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